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Background: Solid lipid nanoparticles (SLNs) are colloidal carrier systems which provide 
controlled-release profiles for many substances. In this study, we prepared aqueous dispersions 
of lipid nanoparticles using a modified, pH-sensitive derivative of phosphatidylethanolamine.
Methods: SLNs were prepared using polysorbate 80 as the surfactant and tripalmitin glyceride 
and N-glutaryl phosphatidylethanolamine as the lipid components. Particle size, polydispersity 
index, and zeta potential were examined by photon correlation spectroscopy. Morphological 
evaluation was performed using scanning electron microscopy, atomic force microscopy, and 
differential scanning calorimetry.
Results: Photon correlation spectroscopy revealed a particle hydrodynamic diameter of 
165.8 nm and zeta potential of −41.6.0 mV for the drug-loaded nanoparticles. Atomic force 
microscopy investigation showed the nanoparticles to be 50–600 nm in length and 66.5 nm in 
height. Differential scanning calorimetry indicated that the majority of SLNs possessed less 
ordered arrangements of crystals compared with corresponding bulk lipids, which is favorable 
for improving drug-loading capacity. Drug-loading capacity and drug entrapment efficiency 
values for the SLNs were 25.32% and 94.32%, respectively.
Conclusion: The SLNs prepared in this study were able to control the release of triamcinolone 
acetonide under acidic conditions.
Keywords: solid lipid nanoparticles, high-shear homogenization, triamcinolone acetonide, 
tripalmitin, phosphatidylethanolamine
Introduction
Solid lipid nanoparticles (SLNs) were developed in the early 1990s as an alternative 
carrier system to traditional colloidal systems, including emulsions, liposomes, and 
polymeric microparticles and nanoparticles.1 Tremendous progress has been made 
in the treatment of disorders using new drug delivery systems, including SLNs, 
which are made from solid lipids (ie, lipids solid at room temperature as well as body 
  temperature) and stabilized by surfactant(s).2 They are generally composed of a solid 
hydrophobic core with a monolayer of phospholipids or phospholipid-derived coating. 
The solid core contains the active drug dissolved or dispersed in a solid fat matrix 
with the hydrophobic ends of the phospholipid chains embedded in the fat matrix. 
Thus, they have the potential to carry lipophilic or hydrophilic drug(s) for diagnostic 
purposes.3–5
A clear advantage of SLNs over polymeric nanoparticles is the fact that the lipid 
matrix is made from physiologically tolerated lipid components, which decreases the 
potential for acute and chronic toxicity.5,6 SLNs have fewer storage and drug leakage International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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problems compared with systems such as liposomes and also 
have good stability for 2–3 years.6–9
It is noteworthy that tumors and inflamed tissues are often 
associated with leaky vascular architecture as a result of the 
poorly regulated nature of tumor angiogenesis. Furthermore, 
the acidity of these regions differs from physiological pH. 
Therefore, the use of acid-sensitive drug carriers has been one 
of the most extensively studied active triggering strategies.10,11 
Dong and Hoffman prepared and reported pH-sensitive 
hydrogels for drug delivery.12 Oh and Lee created a novel 
vector for delivery of anticancer therapy to solid tumors using 
diafiltration to synthesize pH-sensitive polymeric micelles, 
and observed that release of doxorubicin as micelles was 
triggered at pH 6.8.13 Reddy and Low prepared a pH-sensitive 
lipid formulation from dioleylphosphatidylethanolamine and 
citraconic anhydride, and used this to prepare liposomes. 
They observed that the resulting liposomes were stable at 
neutral pH but fusogenic at pH 5.11
The nature of tumor angiogenesis enables submicron-
sized particulate matter, such as SLNs, to penetrate 
preferentially into tumor tissue and be retained there. 
Consequently, tumor-specific drug delivery is attracting 
considerable attention in cancer therapy.7,14–16 Moreover, 
with advances in surface engineering technology, the 
biodistribution of SLNs can be further manipulated by 
modifying the surface physicochemical properties of SLNs 
to target them to the tissue of interest, particularly to tumors 
and inflamed tissue.7,17 So far, researchers have prepared 
various derivatives of phospholipids and used them on the 
outer shells of SLNs.18
The aim of the present study was to investigate the 
feasibility of the inclusion of triamcinolone acetonide 
into surface-modified solid lipid nanoparticles. For this 
purpose, nanoparticles were covered with modified 
phosphatidylethanolamine as an outer shell. Triamcinolone 
acetonide is usually administered via the parenteral route to 
treat inflammatory disorders and cancer of the lymph nodes. 
It is a drug with poor water solubility and high lipophilicity, 
which makes it suitable for SLN encapsulation and in 
vitro characterization. SLN release has been studied using 
lyophilized nanoparticles in different media. Modified high 
shear homogenization and ultrasound techniques have been 
used to produce low particle sizes and high encapsulation 
efficiency,19 while photon correlation spectroscopy, 
differential scanning calorimetry, atomic force microscopy, 
and scanning electron microscopy have been used for their 
characterization.
Materials and methods
The following materials were obtained from the indicated 
sources and used in our study without further purification. 
Tripalmitin glyceride was purchased from Alfa Aesar 
(Germany), and phosphatidylethanolamine and triamcinolone 
acetonide from Sigma-Aldrich (St Louis, MO). Glutaric 
anhydride, polysorbate 80, and sucrose were obtained 
from Merck (Darmstadt, Germany). High-pressure liquid 
chromatography (HPLC) grade methanol and analytical 
grade chloroform and ethanol were also purchased from 
Merck. Other reagents were of analytical or HPLC grade. 
Double-distilled water was prepared in our laboratory.
Preparation of modified 
phosphatidylethanolamine
For preparation of modified phosphatidylethanolamine, 
5 mg of lipid was dissolved in 10 mL of chloroform, and 
an approximately five-fold molar excess (3.85 mg) of 
  glutaric anhydride was then added in the presence of 7.5 µL 
pyridine, and the mixture was incubated at 20°C for 5 hours.20 
Modified phosphatidylethanolamine was identified by iodine 
staining.21 N-glutaryl phosphatidylethanolamine was   isolated 
using plate chromatography and chloroform-methanol 
(65:35 v/v) as the solvent, with a yield of 90%:
1H NMR (200 MHz, CDCl3) δ 0.88 (6H), 1.30 (32 H), 
1.59 (4H), 1.99 (2H), 2.16 (8H), 2.27 (6H), 2.61 (2H), 3.48 
(2H), 3.95 (2H), 4.13 and 4.38 (2H), 4.20 and 4.51 (2H), 
4.71 (1H), 5.33 (4H), and 7.38 (1H) that peaked in 7.38 ppm 
indicated amidic hydrogen.
Preparation of aqueous sLNs and 
lyophilization
Triamcinolone acetonide (0.75% w/v), tripalmitin glyceride 
(2% w/v), and N-glutaryl phosphatidylethanolamine 
(0.5% w/v) were dissolved in 10 mL of chloroform and 
methanol mixture (1:1). Organic solvents were completely 
removed using a rotoevaporator (Laborota 4003, Heidolph, 
Schwabach, Germany). The drug-embedded lipid layer 
was melted by heating at 70°C above the melting point of 
the lipid. An aqueous phase was prepared by dissolving 
polysorbate 80 (1% w/v) in double-distilled water and heated 
to the same temperature as the oil phase. The hot aqueous 
phase was added to the oil phase, and homogenization 
was achieved (at 10,000 rpm and 70°C) using a Diax 900 
homogenizer (Heidolph) for 2 minutes. The resulting coarse 
hot oil in water emulsion was ultrasonicated using a Sonoplus 
ultrahomogenizer (Bandelin, Germany) for 15 minutes. International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Triamcinolone acetonide-SLNs were obtained by allowing 
the hot nanoemulsion to cool off at room temperature.
Sucrose was used in the freeze-drying process as a 
cryoprotector at a concentration of 3 wt%.22 The SLN sus-
pension was frozen in an aqueous sucrose solution at −70°C 
overnight, and the sample was subsequently transferred to 
the freeze-drier (ZiRBuS Technology VaCo 5, D-37539) at 
−50°C for 72 hours, and finally the SLN powder was col-
lected for further experiments.
Determination of entrapment efficiency 
and drug-loading capacity
The percentage of incorporated triamcinolone acetonide 
(entrapment efficiency) was determined by spectropho-
tometric determination at 234 nm using an Agilent 8453-
spectrophotometer, after ultracentrifugation of the aqueous 
dispersion (40,000 rpm for 45 minutes). The amount of free 
drug was detected in the supernatant and the amount of incor-
porated drug was calculated as the initial drug minus the free 
drug. The drug entrapment efficiency and drug-loading in the 
SLNs were calculated using equations (1) and (2):
  EE (%) =
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W
100
as
a
−
×

 
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    (1)
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×

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    (2)
where EE is entrapment efficiency, DL is drug-loading, and 
Wa, Ws, and WL are the weight of drug added into the system, 
analyzed weight of drug in the supernatant, and weight of 
lipid added into the system, respectively.23
Particle diameter, polydispersity index, 
and zeta potential
Measurement of hydrodynamic diameter, polydispersity 
index, and zeta potential of the nanoparticles was accom-
plished using photon correlation spectroscopy (Nano 
ZS4700, Malvern Instruments, Worcestershire, UK). For 
size measurement, all formulations were diluted by deion-
ized water to eliminate the effect of viscosity caused by the 
ingredients. Zeta potential measurements were conducted 
for samples prepared for size measurement. Hydrodynamic 
diameter and zeta potential were reported as the mean of three 
measurements at 25°C. The refractive index of the SLNs and 
water was set at 1.35 and 1.33, respectively.
scanning electron microscopy
In order to verify the result, the morphology of the triam-
cinolone acetonide-SLNs was studied by scanning electron 
microscopy using a Philips XL30 microscope at an acceler-
ating voltage of 10 kV . One droplet of SLN nanosuspension 
was placed on an aluminum specimen stub. After oven-drying 
for 12 hours, the sample was coated with a platinum layer 
using an SCDOOS sputter coater (BAL-TEC, Sweden) in 
an argon atmosphere. Subsequently, the sample was scanned 
and photomicrographs were obtained.
Atomic force microscopy
The surface properties of the drug-loaded SLNs were 
visualized using an atomic force microscope (Mobile 
S, Nanosurf, Switzerland). Explorer atomic force microscopy 
was in noncontact mode, using high resonant frequency (F0 
170 kHz) pyramidal cantilevers with silicon probes having 
dynamic force. The sample was diluted with distilled water 
and then dropped onto a freshly cleaved mica plate, followed 
by vacuum drying for 24 hours at 25°C.
Differential scanning calorimetry
The thermal characteristics of the SLNs and pure drug 
were determined using a differential scanning calorimeter 
(Shimadzu DSC-60, single heating ramp 0°C–300°C, heated 
at 5°C/minute) under a dry nitrogen atmosphere. Samples 
(7–8 mg) were placed in an aluminum pan and heated at 
a rate of 5°C/minute. Empty aluminum pans were used as 
references, and the entire thermal behavior was studied under 
a nitrogen purge.
Assay for triamcinolone acetonide
A simple and sensitive HPLC method with ultraviolet detection 
was used for analysis of triamcinolone acetonide.20 The 
triamcinolone acetonide concentration was determined using 
an HPLC system (LC-10AS Liquid Chromatograph,   SCL-10A 
System Controller, SIL-10AV UV-Vis Detector, C-R6A 
  Chromatopac, Shimadzu, Japan). The analytical conditions 
were as follows: column C18, HPLC Pack column, Inertsil 
ODS, 5 µm, 4.6 × 250 mm (GL Sciences Inc, Japan); ultraviolet 
detection, 240 nm; mobile phase, methanol; water 50:50 (v/v); 
flow rate 1 mL/minute; and injection volume 25 µL.
In vitro release of triamcinolone 
acetonide from sLNs
This experiment was conducted using a static horizontal 
Franz diffusion cell to evaluate the amount of triamcinolone International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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  acetonide released from each formulation.24 A   cellulose 
  acetate membrane with a molecular weight cutoff of 
12,000 Da and a surface area of 2.0 cm2 was used and 
mounted on the Franz diffusion cell. The receptor medium 
was precisely 50 mL in volume and composed of an aque-
ous solution of physiological saline, phosphate-buffered 
saline, and 20% ethanol at four pH values of 4.0, 5.0, 6.0, 
and 7.4, stirred by a magnetic bar at 500 rpm to homogenize 
the medium. Each formulation, 10 mg in 1 mL volume, was 
loaded onto the membrane in the donor compartment. The 
temperature of the assay was controlled at precisely 37°C. 
At predetermined time intervals, 1 mL aliquots of the release 
medium were withdrawn using a syringe needle, and the same 
volumes of freshly prepared receptor medium were added. 
The samples were analyzed using an HPLC method described 
previously.20 The experiments were repeated three times and 
the results were expressed as means ± standard deviation.
Results and discussion
Preparation of nanoparticles, drug 
entrapment efficiency, and loading 
capacity
In this study, homogenization was performed at above 
the melting point of the lipid followed by ultrasonica-
tion for preparation of modified SLN.25,26 To disperse the 
triamcinolone acetonide homogeneously in the lipid, a 
chloroform/methanol solvent system was used and homog-
enized for 2 minutes.27 Subsequently, the prepared SLNs 
were subjected to further lyophilization. Our preliminary 
studies showed that reconstitution of freeze-dried SLNs was 
impossible when they were freeze-dried without addition of 
cryoprotectants. Therefore, a 1:1 dilution with 3% w/w of 
sucrose as a cryoprotectant was performed.28
Many different drugs have been incorporated in the 
SLNs.17 The prerequisite for obtaining a sufficient loading 
capacity is a sufficiently high solubility of the drug in the lipid 
melt. Relatively higher encapsulation efficiency constitutes 
one of the major advantages of SLNs.
For calculations of entrapment efficiency and loading 
capacity, calibration curves for the ultraviolet assays of 
triamcinolone acetonide were conducted on eight solutions 
in the concentration ranges of 1.5 × 10–3 to 1.25 × 10–4 mol/L; 
encapsulation efficiency and drug-loading were 94.32% and 
25.32%, respectively. The high entrapment efficiency of the 
drug is thought to be the result of the lipophilic characteristics 
and high compatibility between the drug and the lipid. 
Furthermore, the high encapsulation efficiency and drug-
loading in comparison with previous work24 is a result of 
the method of preparation and mixing of the drug and lipid 
matrix in the organic solvents.
Nanoparticle characterization
The mean particle size, polydispersity index and zeta 
potential of the SLNs with and without drug were measured 
by photon correlation spectroscopy, as summarized in 
Table 1. The mean particle sizes of 165.8 nm and 97.44 nm 
were obtained for drug-loaded and free SLNs, respectively 
(Table 1). The increase in size after drug loading must be 
due to incorporation of the drug in the nanoparticle matrix.23 
The polydispersity index is a ratio providing information 
about the homogeneity of particle size distribution in a 
given   system, and ideally, this should be ,0.3.29 Triamcinolone 
acetonide-loaded and free SLN had polydispersity index 
values of 0.254 and 0.337, respectively, indicating that the 
nanoparticles had a narrow size distribution, and suggesting 
nanoparticle monodispersity.30,31 The zeta potential is a key 
factor for evaluation of the stability of a colloidal dispersion.23 
When the absolute value of the zeta potential is higher than 
30 mV for a colloidal formulation, the particles are likely to 
be electrochemically stable under the investigated condition.25 
Zeta potential values of −41.6 mV and −43.0 mV were obtained 
for the drug-loaded and free SLNs, respectively (Figure 1). As 
Table 1 demonstrates, as time passes, increases are observed in 
size, polydispersity index, and zeta potential as a result of light 
and other factors that cause gelation.32 However, it is obvious 
from these values that the prepared nanosuspension has an 
acceptable electrochemical and physical stability potential for 
3 and 6 months of storage.
Similarly, in order to evaluate the stability of SLNs 
lyophilized powder after 6 months, 10 mg of sample was 
Table 1 Particle size polydispersity index and zeta potential for drug-loaded and free solid lipid nanoparticles in colloidal suspension
Free nanoparticles Drug-loaded nanoparticles
Size (nm) pDI ZP (mV) Size (nm) PDI ZP (mV)
Freshly prepared 97.44 0.347 −43.0 165.8 0.254 −41.6
After 3 months 117.4 0.337 −25.8 173.0 0.329 −40.0
After 6 months 167.6 0.346 −20.7 193.5 0.334 −23.3
Abbreviations: PDI, polydispersity index; ZP, zeta potential.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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dispersed in distilled water and characterized. The values 
for particle diameter, polydispersity index, and zeta potential 
were 223.3 nm, 0.321, and −30.1, respectively. These results 
indicate that, using sucrose as a cryoprotectant, the particle 
size remains in the nanometric range.
In order to obtain a scanning electron microscopic image, 
we used freshly prepared SLN loaded with triamcinolone 
acetonide, and micrographs of the samples containing 
drug-loaded SLNs are shown in Figure 2. The micrographs 
demonstrated a spherical shape and a smooth surface, with 
a particle size in the nanometric range.25
The atomic force microscopy technique has been widely 
used to obtain size, shape, and surface morphological infor-
mation about nanoparticles. It is capable of resolving surface 
details down to 0.01 nm and producing a contrasted and 
three-dimensional image of the sample.23 A drop of diluted 
aqueous suspension (without preliminary ultrafiltration) was 
placed on a mica slide and dried out at room temperature 
for 24 hours. Figure 3 gives the tapping mode atomic force 
microscopic images of freshly prepared SLN containing 
triamcinolone acetonide after 24 hours (A and B), 48 hours 
(C and D), and 1 week (E and F). The nanoparticle images 
demonstrated spherical particles of 50–600 nm in diameter, 
but only 66.5 nm in height. After 48 hours, the nanoparticles 
were uniformly grown on mica slides, as illustrated in 
  Figure 3 (C and D). One week after spreading SLNs onto the 
mica plates, no particles could be distinguished in the atomic 
force microscopic images, which showed homogeneous 
and flat shapes, as illustrated in Figure 3 (E and F).33 This 
result is not surprising, considering the well known ability 
of particles to fuse during evaporation of water consequent 
to the molecular diffusion on the surface of the particles. 
Moreover, the presence of free surfactant in the suspension 
may increase the characteristic size.33
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Differential scanning calorimetry thermograms for triam-
cinolone acetonide, tripalmitin glyceride, a physical mixture 
of triamcinolone acetonide, tripalmitin glyceride, modified 
phosphatidylethanolamine, and lyophilized SLNs are shown 
in Figure 4. A sucrose thermogram is also shown in this figure 
to demonstrate peaks of lyophilized SLNs. The triamcinolone 
acetonide powder showed a sharp melting process with an 
onset temperature of 284.72°C and a peak of 286.04°C, with 
a melting enthalpy of 64.73 J/g. This was confirmed by the 
presence of a melting peak for triamcinolone acetonide in the 
physical mixture. However, no melting process was observed 
for the lyophilized SLN suspension. This suggested that 
there was no crystalline triamcinolone acetonide in the SLN 
suspension, and triamcinolone acetonide might be present 
in an amorphous state. Similar results have been reported 
by previous researchers, stating that rapid quenching of the 
nanoemulsion does not allow the drug to crystallize.26,27 An 
endothermic peak of the sucrose used as a cryoprotectant 
was observed at 170.21°C in the triamcinolone acetonide-
SLN curve. Meanwhile, the melting peak temperature of 
tripalmitin glyceride in lyophilized SLN (57.73°C) was 
diminished when compared with the temperature of the 
bulk lipid (64.38°C). The decrease in melting point can be 
attributed to the small size (nanometer range), high specific 
surface area, and presence of a surfactant.15,30 This can also 
be attributed to the Kelvin effect and is described by the 
Thomson equation.3 Moreover, the lower melting enthalpy 
value of 35.72 J/g indicates a less ordered lattice arrange-
ment of lipids within the nanoparticles compared with the 
bulk materials.9
In vitro drug release
In this study, the in vitro release of triamcinolone acetonide 
from SLNs was investigated for 60 hours at 37°C using a 
Franz diffusion cell (Figure 5). Due to the low water solubility 
of triamcinolone acetonide, 20% ethanol was added to the 
phosphate-buffered solution at four pH values of 4.0, 5.0, 6.0, 
and 7.4.24 Our results showed that up to 50% was released 
over the test period. The prolonged and lower release of 
SLNs after 12 hours can be explained by slower diffusion of 
triamcinolone acetonide from the inner solid core matrix of the 
formulations. However, the initial fast release was detected at 
a lower pH. In this experiment, we studied the release profile 
of pure drug compared with nanoparticles in acidic pH, and the 
release half-life of drug release was significantly diminished 
compared with nanoparticles (about 25 minutes).
The release data were analyzed using the following 
Higuchi kinetic equation:25 Q t = k·t0.5, where Qt is the International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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  percentage of drug released at time t, and k is the release rate 
constant. Regarding the release model of all formulations, it 
was found that the prolonged release characteristic of triam-
cinolone acetonide was well fitted to Higuchi’s square root 
model, as has been reported for drug-loaded SLN systems.25,34,35 
Linear fits were obtained, indicating that the release profile 
of triamcinolone acetonide from homogenous and granular 
matrix systems is diffusion-controlled. The R2 values from 
in vitro release kinetics and the K values or release rate 
constant obtained from the Higuchi model plot are presented 
in Table 2. Furthermore, as shown in Figure 6 and the in vitro 
release data, we found that the burst release was increased 
with a decline in pH that demonstrates a change in structure 
of the phospholipids and release of the terminal anhydride. 
Several previous studies have been conducted to identify a 
pH-sensitive carrier preparation, and often the amount of 
drug release from SLNs was small compared with our results, 
and the values for common SLNs without modification were 
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below 25%.8,25,27 Subedi et al investigated pH-sensitive SLNs 
and used them for doxorubicin delivery; in their work, 30% 
of the drug was released after 24 hours.8
Venkateswarlo and Manjunath investigated SLNs of 
tripalmitin and used them as clozapine carriers, and in their 
work, up to 20% of drug was released after 48 hours.25 Liu 
et al investigated SLNs containing triamcinolone acetonide in 
mixtures of monoglycerides, diglycerides, and triglycerides 
of palmitic acid and stearic acid, and found that the drug was 
released more slowly compared with our prepared carrier.24 
The simple mechanism for terminal release of anhydride from 
modified polyethylene is shown in Figure 6. This pathway 
was faster at an acidic pH of 4. Nevertheless, it is certain that 
this carrier requires further in vitro and in vivo studies.
Conclusion
As mentioned above, SLNs offer an attractive means of drug 
delivery, particularly for poorly water-soluble drugs. They 
combine the advantages of polymeric nanoparticles, fat emul-
sions, and liposomes. In this study, modified N-  glutaryl-phos-
phatidylethanolamine was prepared, used for SLN preparation, 
and characterized. The results indicate that the carrier has 
suitable stability in colloidal form and may increase drug 
release under acidic conditions. Homogenization   followed 
by ultrasonication is suitable for producing small SLNs with 
an average diameter of 165.8 nm. Using a   Zetasizer, atomic 
force microscopy, and SEM, the diameter and morphology 
of the particles was investigated. Zeta potential data indicate 
the stability of the nanosuspension. After 6 months, Zeta-
sizer data did not indicate any obvious changes in diameter, 
polydispersity index, and zeta potential. An in vitro study 
indicated an increase in burst release and a pH decrement 
as well. In vitro release kinetics coincide with the Higuchi 
equation. These observations suggest that the present system 
offers an exciting mode of target delivery for potent lipophilic 
anticancer drugs and anti-inflammatory agents.
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Table 2 r2 and K for drug-release experiment in four types of receptor medium
Receptor pH 4 5 6 7.4
r2 0.989 ± 0.0034 0.981 ± 0.0046 0.985 ± 0.007 0.980 ± 0.0025
K 0.119 ± 0.013 0.102 ± 0.018 0.092 ± 0.011 0.086 ± 0.018
Notes: r2 determination coefficient and k dissolution rate constant (µg/mL/h−1/2). each value represents the mean of three experiments ± standard deviation.
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Figure 6 Terminal release of anhydride from modified phosphatidylethanolamine.International Journal of Nanomedicine
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